LUISA LINA VILLA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Radiologia, Faculdade de Medicina - Docente
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder
57 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 57
- Correlation of a microRNA expression profile and the prognosis of penile cancer: A prospective study using microarray data analysis(2018) FURUYA, Tatiane K.; MURTA, Claudio B.; PONTES JR., Jose; UNO, Miyuki; CARRASCO, Alexis; SICHERO, Laura C.; VILLA, Luisa L.; COELHO, Rafael F.; GUGLIELMETTI, Giuliano B.; CORDEIRO, Mauricio D.; LEITE, Katia R.; SROUGI, Miguel; CHAMMAS, Roger; NAHAS, William C.
conferenceObject TISSUE EXPRESSION OF SUPEROXIDE DISMUTASE-2 AS A MARKER OF INTRAEPITELIAL NEOPLASIA AND INVASIVE CERVICAL CARCINOMA(2015) RABELO-SANTOS, S. H.; VILLA, L. L.; TERMINI, L.; LONGATTO, A.; ANDREOLI, M. A.; ANGELO-ANDRADE, L. A. L.; DERCHAIN, S.; ZEFERINO, L. CarlosconferenceObject Co-infection with Epstein-Barr virus impacts oral HPV persistence(2022) DICKEY, Brittney L.; GIULIANO, Anna R.; SIRAK, Bradley; ABRAHAMSEN, Martha; LAZCANO-PONCE, Eduardo; VILLA, Luisa L.; COGHILL, Anna E.conferenceObject HPV-positive tumor cell lines exhibit major alterations in Toll-like receptor pathways and depend on HMGB1 expression(2018) MORALE, Mirian Galliote; ABJAUDE, Walason da Silva; SILVA, Aline Montenegro da; VILLA, Luisa Lina; BOCCARDO, Enrique- Planning cancer control in Latin America and the Caribbean(2013) GOSS, Paul E.; LEE, Brittany L.; BADOVINAC-CRNJEVIC, Tanja; STRASSER-WEIPPL, Kathrin; CHAVARRI-GUERRA, Yanin; LOUIS, Jessica St; VILLARREAL-GARZA, Cynthia; UNGER-SALDANA, Karla; FERREYRA, Mayra; DEBIASI, Marcio; LIEDKE, Pedro E. R.; TOUYA, Diego; WERUTSKY, Gustavo; HIGGINS, Michaela; FAN, Lei; VASCONCELOS, Claudia; CAZAP, Eduardo; VALLEJOS, Carlos; MOHAR, Alejandro; KNAUL, Felicia; ARREOLA, Hector; BATURA, Rekha; LUCIANI, Silvana; SULLIVAN, Richard; FINKELSTEIN, Dianne; SIMON, Sergio; BARRIOS, Carlos; KIGHTLINGER, Rebecca; GELRUD, Andres; BYCHKOVSKY, Vladimir; LOPES, Gilberto; STEFANI, Stephen; BLAYA, Marcelo; SOUZA, Fabiano Hahn; SANTOS, Franklin Santana; KAEMMERER, Alberto; AZAMBUJA, Evandro de; ZORILLA, Andres Felipe Cardona; MURILLO, Raul; JERONIMO, Jose; TSU, Vivien; CARVALHO, Andre; GIL, Carlos Ferreira; STERNBERG, Cinthya; DUENAS-GONZALEZ, Alfonso; SGROI, Dennis; CUELLO, Mauricio; FRESCO, Rodrigo; REIS, Rui Manuel; MASERA, Guiseppe; GABUS, Raul; RIBEIRO, Raul; KNUST, Renata; ISMAEL, Gustavo; ROSENBLATT, Eduardo; ROTH, Berta; VILLA, Luisa; SOLARES, Argelia Lara; LEON, Marta Ximena; TORRES-VIGIL, Isabel; COVARRUBIAS-GOMEZ, Alfredo; HERNANDEZ, Andres; BERTOLINO, Mariela; SCHWARTSMANN, Gilberto; SANTILLANA, Sergio; ESTEVA, Francisco; FEIN, Luis; MANO, Max; GOMEZ, Henry; HURLBERT, Marc; DURSTINE, Alessandra; AZENHA, GustavoNon-communicable diseases, including cancer, are overtaking infectious disease as the leading health-care threat in middle-income and low-income countries. Latin American and Caribbean countries are struggling to respond to increasing morbidity and death from advanced disease. Health ministries and health-care systems in these countries face many challenges caring for patients with advanced cancer: inadequate funding; inequitable distribution of resources and services; inadequate numbers, training, and distribution of health-care personnel and equipment; lack of adequate care for many populations based on socioeconomic, geographic, ethnic, and other factors; and current systems geared toward the needs of wealthy, urban minorities at a cost to the entire population. This burgeoning cancer problem threatens to cause widespread suffering and economic peril to the countries of Latin America. Prompt and deliberate actions must be taken to avoid this scenario. Increasing efforts towards prevention of cancer and avoidance of advanced, stage IV disease will reduce suffering and mortality and will make overall cancer care more affordable. We hope the findings of our Commission and our recommendations will inspire Latin American stakeholders to redouble their efforts to address this increasing cancer burden and to prevent it from worsening and threatening their societies.
- HPV infection and cervical neoplasia: associated risk factors(2015) RIBEIRO, Andrea Alves; COSTA, Maria Cecilia; ALVES, Rosane Ribeiro Figueiredo; VILLA, Luisa Lina; SADDI, Vera Aparecida; CARNEIRO, Megmar Aparecida dos Santos; ZEFERINO, Luiz Carlos; RABELO-SANTOS, Silvia HelenaBackground: Behavioral risks such as age at first sexual intercourse, number of sexual partners and partner's sexual behavior are associated with an increased risk of HPV infection, persistence of the infection and the development of neoplastic precursor lesions. The objective of this study was to evaluate the risk factors associated with HPV positivity and with a diagnosis of cervical neoplasia in women referred with an abnormal cervical smear. Methods: This study evaluated a series of 198 women referred with an abnormal cervical smear. Risk factors for HPV infection were investigated using a questionnaire. All cervical specimens were tested for 27 HPV genotypes using the Roche polymerase chain reaction reverse line blot assay. Results: The overall prevalence of HPV was 87 %. First sexual intercourse before 16 years of age was significantly associated with a positive HPV test (OR 4.41; 95 % CI: 1.20 - 19.33; p = 0.01). A significant association was also found between this risk factor and CIN 1 lesions or worse (OR 2.2; 95 % CI 0.94 - 5.08; p = 0.03). Conclusions: The age at which a woman begins to be sexually active is associated with HPV infection and with a diagnosis of cervical neoplasia.
conferenceObject Cervical cancer immunomodulation through stat3 and p65 NF kappa b: Effects beyond the tumor microenvironment.(2020) ROSSETTI, Renata Ariza Marques; RODRIGUEZ, Gretel Rodriguez; SILVA JR., Ildelfonso Alves Da; CARVALHO, Jesus De Paula; ROSA, Maria Beatriz Sartor De Faria; VILLA, Luisa Lina; LEPIQUE, Ana Paula- Cervical Cancer in Latin America and the Caribbean: The Problem and the Way to Solutions(2012) VILLA, Luisa LinaLatin America and the Caribbean have one of the highest incidence and mortality rates from cervical cancer in the world. In this region, age-adjusted incidence rates range from 20 to 80 per 100,000 women per year. Overall, the mortality rates are extremely high in spite of the availability of Pap screening in several countries. Women from lower socioeconomic status, often less educated, are unaware of cervical cancer screening or have no access to it. Despite the efforts to reorganize screening programs in the region, in a few countries, only a slight decrease in cervical cancer mortality has been observed. New modalities for primary and secondary screening should be evaluated and disseminated, including HPV testing and vaccination against the most common HPV types. HPV prophylactic vaccines were approved in most Latin American countries, but only few are considering its implementation in national immunization programs. Besides cost and other logistical issues, lack of recommendation by policy makers or lawmakers is deterring the introduction of HPV vaccines in the region. Furthermore, studies conducted in the region have indicated that HPV vaccination only or vaccination supplemented with screening may be considered a cost-effective strategy to reduce mortality by cervical cancer. Cancer Epidemiol Biomarkers Prev; 21(9); 1409-13. (C) 2012 AACR.
- The Association between Smoking and Anal Human Papillomavirus in the HPV Infection in Men Study(2022) UMUTONI, Victoria; SCHABATH, Matthew B.; NYITRAY, Alan G.; WILKIN, Timothy J.; VILLA, Luisa L.; LAZCANO-PONCE, Eduardo; GIULIANO, Anna R.; SUDENGA, Staci L.Background: Previous studies show an association between smoking and anal cancer. The objective of this study was to assess the association between smoking and anal HPV (human papillo-mavirus) prevalence, incidence, and persistence in men. Methods: The HPV Infection in Men (HIM) Study is a multinational study that enrolled HIV-negative men. At baseline and follow-up visits, anal specimens were collected. HPV geno-typing was assessed by linear array. Prevalence ratios (PR) were used to assess the association between smoking and anal HPV prevalence. Odds ratios (OR) were used to assess the association between smoking and anal HPV incidence and >= 12-months persistence. Results: Current smokers have a higher prevalence [adjusted PR (aPR), 1.36; 95% confidence interval (CI), 1.06-1.73) and incidence [adjusted OR (aOR), 1.74; 95% CI, 1.26-2.39] and >= 12-months persistence (aOR, 1.67; 95% CI, 1.19-2.33) of any anal HPV compared with never smokers. There were no differences in the prevalence, incidence, or persistence of anal HPV between former and never smokers. Smoking status was not associated with the prevalence or persistence of anal HPV among men who have sex with men but was associated with higher incidence of HR-HPV. Among men that have sex with women (MSW), current smokers had an increased prevalence and incidence of LR-HPV compared with never smokers. Conclusions: Current smokers had a higher prevalence, persistence, and incidence of HPV compared with never smokers. Further research is needed to assess the role smoking in anal HPV persis-tence and progression to disease. Impact: Prevention initiatives should raise awareness about smoking and the risk factor of anal HPV infection and anal cancer.
- HPV-16 E7 expression up-regulates phospholipase D activity and promotes rapamycin resistance in a pRB-dependent manner(2018) RABACHINI, Tatiana; BOCCARDO, Enrique; ANDRADE, Rubiana; PEREZ, Katia Regina; NONOGAKI, Suely; CUCCOVIA, Iolanda Midea; VILLA, Luisa LinaBackground: Human Papillomavirus (HPV) infection is the main risk factor for the development and progression of cervical cancer. HPV-16 E6 and E7 expression is essential for induction and maintenance of the transformed phenotype. These oncoproteins interfere with the function of several intracellular proteins, including those controlling the PI3K/AKT/mTOR pathway in which Phospolipase D (PLD) and Phosphatidic acid (PA) play a critical role. Methods: PLD activity was measured in primary human keratinocytes transduced with retroviruses expressing HPV-16 E6, E7 or E7 mutants. The cytostatic effect of rapamycin, a well-known mTOR inhibitor with potential clinical applications, was evaluated in monolayer and organotypic cultures. Results: HPV-16 E7 expression in primary human keratinocytes leads to an increase in PLD expression and activity. Moreover, this activation is dependent on the ability of HPV-16 E7 to induce retinoblastoma protein (pRb) degradation. We also show that cells expressing HPV-16 E7 or silenced for pRb acquire resistance to the antiproliferative effect of rapamycin. Conclusion: This is the first indication that HPV oncoproteins can affect PLD activity. Since PA can interfere with the ability of rapamycin to bind mTOR, the use of combined strategies to target mTOR and PLD activity might be considered to treat HPV-related malignancies.